Spinal Muscular Atrophy (SMA)
Rare Disease·MeSH: Muscular Atrophy, Spinal
Prevalence
5.0 / 100K
5 drugs in development·4 companies·1 clinical trial
Drug Pipeline by Phase
Approved(1)
| Drug | Company |
|---|---|
| Evrysdi | PTC THERAPEUTICS, INC. (PTCT) |
Phase 2(1)
| Drug | Company |
|---|---|
| argx-119 iv | ARGENX SE (ARGX) |
Phase 1(1)
| Drug | Company |
|---|---|
| avxs-101 | AveXis, Inc. (AVXS) |
Preclinical(2)
Compare drugs
Frequently asked questions
How many drugs are in development for Spinal Muscular Atrophy (SMA)?
BioSniper tracks 5 drugs in development for Spinal Muscular Atrophy (SMA) across 4 companies.
How many clinical trials target Spinal Muscular Atrophy (SMA)?
There are 1 clinical trial targeting Spinal Muscular Atrophy (SMA) tracked by BioSniper.
What is the prevalence of Spinal Muscular Atrophy (SMA)?
The estimated prevalence of Spinal Muscular Atrophy (SMA) is approximately 5.0 per 100,000 population.
Deep-dive into Spinal Muscular Atrophy (SMA)
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis